Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540729 | NSE Symbol : | ISIN : INE695X01011 | Industry : Miscellaneous |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
03-Dec-2024	06-Dec-2024	Increase in Authorised Capital	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/12/2024 inter alia to consider and approve conversion of unsecured loans from Promoters and others into equity shares and increase in the authorized capital as per requirement Outcome of Board Meeting held on 06.12.2024 (As Per BSE Announcement dated on 06.12.2024)
11-Nov-2024	14-Nov-2024	Half Yearly Results	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve un-audited financial statements of 30.09.2024 and to consider conversion of unsecured loans into equity shares Outcome of Board Meeting held on 14.11.2024 (As Per Bse Announcement Dated on 14.11.2024)
06-Sep-2024	06-Sep-2024	AGM	Outcome of Board Meeting held on 06.09.2024 - Reappointment of Independent Directors, Secretarial & Internal Auditors and regarding 8th AGM of the Company
10-Jul-2024	19-Jul-2024	Accounts	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/07/2024 inter alia to consider and approve the financial results for the half year and year ended 31.03.2024 Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 ,inter alia, to consider and approve the Standalone and Consolidated financial results of the Company for the half year and year ended 31.03.2024 and to take note of the report of the Auditors on the same and other matters. The proposed meeting to be held today i.e. 17.07.2024 is now postponed to 19.07.2024 (As per BSE Announcement Dated on 17/07/2024) Outcome of Board Meeting held on 19.07.2024 (As Per BSE Announcement Dated on: 18/07/2024) Submission of revised financial statements for the period ended 31.03.2024 pursuant to query from BSE regarding bifurcation of Trade Payables (As Per BSE Announcement Dated on 19.09.2024)
01-Apr-2024	01-Apr-2024	Change in Other Executives	Appointment of CS and Compliance Officer w.e.f 01.04.2024
08-Nov-2023	14-Nov-2023	Half Yearly Results	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve the un-audited financial results of the Company for the half year ended 30.09.2023 and to take note of the Statutory Auditors limited review reports thereon. Outcome of Board Meeting held on 14.11.2023 Change in Designation of Dr. Vyasmurti Madhavrao Shingatgeri from WTD to Non Executive Director w.e.f 14.11.2023 (As Per BSE Announcement Dated on 14/11/2023)
04-Aug-2023	10-Aug-2023	Half Yearly Results	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the financial results of the Company for the half year ended 30.09.2022 and year ended 31.03.2023 Outcome of Board Meeting held on 10.08.2023 Approval of financial statements for the period ended 30.09.2022 and 31.03.2023 (As per BSE Announcement Dated on 10/08/2023)
22-May-2023	30-May-2023	Accounts	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve financial statements for the period ended 30.09.2022 and 31.03.2023 Intimation regarding postponement of Board Meeting dated 30.05.2023 for approval of financial results of the Company (As Per BSE Announcement Dated on 30.05.2023)
08-Nov-2022	14-Nov-2022	Half Yearly Results	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve unaudited financials (standalone & consolidation) for the half year ended 30.09.2022 Delay in submission of financial results for the half year ended 30.09.2022 (As Per BSE Announcement Dated on 14.11.2022)
24-May-2022	30-May-2022	Accounts	Audited Results Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve the Audited Financials (Standalone and Consolidated) for the half year ended 31.03.2022 (As Per BSE Announcement dated on 23.05.2022) Approved the Audited (standalone and consolidated) financials for the half year and year ended 31.03.2022 (As Per BSE Announcement Dated on 30/05/2022)
06-Dec-2021	06-Dec-2021	AGM	5th Annual General Meeting on 31.12.2021 Sub: Outcome of Board Meeting held on December 06, 2021.
03-Nov-2021	11-Nov-2021	Half Yearly Results	Half Yearly Results Unaudited Financial results for half year ended 30.09.2021 (As Per BSE Announcement Dated 11.11.2021)
17-Jun-2021	28-Jun-2021	Accounts	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/06/2021 ,inter alia, to consider and approve 1. The standalone and consolidated audited financial statements of the Company for the half year and year ended March 31, 2021. 2. Raising of capital through preferential allotment of equity shares subject to the requisite approvals from shareholders and BSE Ltd. This is for your information The Board Meeting to be held on 23/06/2021 has been revised to 28/06/2021 The Board Meeting to be held on 23/06/2021 has been revised to 28/06/2021 (As Per BSE Announcement Dated 22.06.2021)
05-Nov-2020	13-Nov-2020	Half Yearly Results	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2020 ,inter alia, to consider and approve the Standalone and Consolidated un-audited Financial Statements of the Company for the half year ended September 30, 2020 and other matters Outcome of Board Meeting held on 13.11.2020 along with unaudited financial results for the half year ended 30.09.2020 (As per BSE Announcement Dated on 13/11/2020)
19-Jun-2020	30-Jun-2020	Accounts	Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2020 ,inter alia, to consider and approve the standalone and consolidated audited financial statements of the Company for the half year and year ended March 31, 2020 and other matters. Outcome of Board Meeting held on 30.06.2020 (As Per BSE Announcement Dated 30.06.2020)

LOGIN HERE

Vanta Bioscience Ltd

Board Meeting